Robert Azelby

Robert W.
Azelby is an Independent Non-Executive Director at ADC Therapeutics SA since 2023.
He is a Non-Executive Director at Autolus Therapeutics Plc starting in 2024.
He serves as an Independent Director at Cardinal Health, Inc. beginning in 2024.
He is an Independent Director at Tango Therapeutics, Inc. starting in 2026.
Formerly, Mr. Azelby was President, Chief Executive Officer & Director at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2019.
He was President, Chief Executive Officer & Director at Climb Bio, Inc. from 2020 to 2023.
He was Chief Executive Officer at Masimo Corp.
from 2024 to 2025.
He was Director at Immunomedics, Inc. in 2020.
He was Director at Cascadian Therapeutics LLC from 2017 to 2018.
He was Independent Director at Clovis Oncology, Inc. from 2018 to 2023.
He was Director at Alliance for Regenerative Medicine.
He was Independent Director at Chinook Therapeutics, Inc. in 2023.
He was Independent Director at Terns Pharmaceuticals, Inc. from 2025 to 2026.
He was Vice President & General Manager-Oncology at Amgen, Inc. from 2012 to 2015.
He was VP-Commercial Effectiveness Unit & General Manager at Amgen Europe BV.
He was Chief Commercial Officer & Executive VP at Juno Therapeutics, Inc. from 2015 to 2018.
Mr. Azelby completed undergraduate studies at the University of Virginia.
He earned an MBA from Harvard Business School in 1997.